8d
Clinical Trials Arena on MSNMacroGenics axes ADC drug following Phase II failure in prostate cancerThe company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.
March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ ... tetravalent PD-1 × CTLA-4 DART ® molecule designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes ...
1 Day MGNX 0.91% DJIA 1.65% Russell 2K 2.53% Health Care/Life Sciences 0.14% ...
FUT Birthday is one of the most iconic promos in Ultimate Team history and it’s back and better than ever in EA FC 25, bringing with it all of the special cards, SBCs and Icons you’d expect.
1 Day MGNX -7.14% DJIA -1.09% Russell 2K -1.10% Health Care/Life Sciences 1.12% ...
MacroGenics has a strong cash position of $240 million ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments ...
MacroGenics has a strong cash position ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments for various ...
NATCHITOCHES, La. -- A Natchitoches woman was killed Friday afternoon in a three-vehicle crash, state police said. The victim is identified as Doris L. Nichols, 58. She was pronounced dead at the ...
ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results